The Use of (Meth)acrylic Copolymers in the Production of Matrix Tablets with Controlled Drug Release

被引:0
作者
Maskova, E. [1 ]
Kubova, K. [1 ]
Vetchy, D. [1 ]
机构
[1] Univ Vet & Pharmaceut Sci, Fac Pharm, Dept Pharmaceut, Brno 61242, Czech Republic
来源
CHEMICKE LISTY | 2015年 / 109卷 / 01期
关键词
Eudragit (R); (meth)acrylic copolymers; matrix tablets; controlled release; INTERPOLYELECTROLYTE COMPLEXES; SUSTAINED-RELEASE; EUDRAGIT(R); HYDROCHLORIDE; DISSOLUTION; FORMULATION; CHITOSAN; BEHAVIOR; DESIGN; RS;
D O I
暂无
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Eudragit (R) polymers are widely used acrylic pharmaceutical excipients. Over recent years, they have often been applied in matrix tablets with controlled drug release to improve the therapeutic activity and patient compliance. Eudragit (R) polymers can be used alone or combined with other poly(meth)acrylates or cellulose derivatives (hypromellose, ethylcellulose). Generally, Eudragit (R) matrices contain a soluble (lactose) or an indifferent filler (microcrystalline cellulose). Eudragit/s (R) is incorporated into matrix tablets to achieve a drug dissolution profile close to zero-order kinetics or the pH-independent release of a drug with pH-dependent solubility. Properties and dissolution behavior of Eudragit (R) matrices can be influenced by their thermal treatment.
引用
收藏
页码:14 / 20
页数:7
相关论文
共 45 条
  • [1] Abd El-Gawad AH, 2012, BRIT J PHARM RES, V2, P17
  • [2] Al-Taani B. M., 2003, AAPS PHARMSCITECH, V4, P3
  • [3] [Anonymous], BRAS J PHARM SCI
  • [4] Apu AS, 2009, TROP J PHARM RES, V8, P145
  • [5] Eudragit NE30D based Metformin/Gliclazide extended release tablets:: Formulation, characterisation and in vitro release studies
    Arno, EA
    Anand, P
    Bhaskar, K
    Ramachandran, S
    Saravanan, M
    Vinod, R
    [J]. CHEMICAL & PHARMACEUTICAL BULLETIN, 2002, 50 (11) : 1495 - 1498
  • [6] Thermal treating as a tool for sustained release of indomethacin from Eudragit RS and RL matrices
    Azarmi, S
    Farid, J
    Nokhodchi, A
    Bahari-Saravi, SM
    Valizadeh, H
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 246 (1-2) : 171 - 177
  • [7] Diclofenac release from Eudragit-containing matrices and effects of thermal treatment
    Billa, N
    Yuen, KH
    Peh, KK
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1998, 24 (01) : 45 - 50
  • [8] Optimization of preparation of matrix pellets containing Eudragit® NE 30D
    Boelcskei, E.
    Regdon, G., Jr.
    Sovany, T.
    Kleinebudde, P.
    Pintye-Hodi, K.
    [J]. CHEMICAL ENGINEERING RESEARCH & DESIGN, 2012, 90 (05) : 651 - 657
  • [9] Ceballos A., 2005, Farmaco (Lausanne), V60, P913, DOI 10.1016/j.farmac.2005.07.002
  • [10] DISSOLUTION RATES OF DIFFERENT DRUGS FROM SOLID DISPERSIONS WITH EUDRAGIT RS
    DEFILIPPIS, P
    ZINGONE, G
    GIBELLINI, M
    RUBESSA, F
    RUPENA, P
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 1995, 3 (05) : 265 - 271